γ-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study

Diabetologia

Volumn 58, Issue 7, 2015, Pages 1484-1493

  Morling, Joanne R ^a   Fallowfield, Jonathan A ^b   Williamson, Rachel M ^c   Robertson, Christine M ^a   Glancy, Stephen ^c   Guha, Indra N ^d   Strachan, Mark W J ^c   Price, Jackie F ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cardiovascular diseases; Community based; Epidemiology; Fatty liver; Type 2 diabetes mellitus; Glutamyltransferase

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOKERATIN 18; GAMMA GLUTAMYLTRANSFERASE; BIOLOGICAL MARKER;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE TO PLATELET RATIO INDEX; ASSESSMENT OF HUMANS; CHRONIC LIVER DISEASE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DIABETIC PATIENT; ECHOGRAPHY; FATTY LIVER; FEMALE; FOLLOW UP; HUMAN; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON ALCOHOLIC FATTY LIVER DISEASE FIBROSIS SCORE; NON INSULIN DEPENDENT DIABETES MELLITUS; PORTAL HYPERTENSION; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM; THROMBOCYTE COUNT; BLOOD; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; ENZYMOLOGY; LIVER CIRRHOSIS; LIVER FUNCTION TEST; SCOTLAND; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; SCOTLAND; TREATMENT OUTCOME;

EID: 84931571647     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3575-y     Document Type: Article

References (44)

1. Calori G, Lattuada G, Ragogna F et al (2011) Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 54:145–152
2. Ekstedt M, Franzen LE, Mathiesen UL et al (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44:865–873
3. Targher G, Bertolini L, Poli F et al (2005) Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54:3541–3546
4. Targher G, Bertolini L, Rodella S et al (2007) Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 30:2119–2121
5. Loria P, Lonardo A, Targher G (2008) Is liver fat detrimental to vessels? Intersections in the pathogenesis of NAFLD and atherosclerosis. Clin Sci (Colch) 115:1–12
6. Adiels M, Taskinen M-R, Borén J (2008) Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep 8:60–64
7. Van Gaal LF, Mertens IL, Christophe E (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444:875–880
8. Feldstein AE, Wieckowska A, Lopez AR, Liu Y-C, Zein NN, McCullough AJ (2009) Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50:1072–1078
9. Wai C-T, Greenson JK, Fontana RJ et al (2003) A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38:518–526
10. Vallet-Pichard A, Mallet V, Nalpas B et al (2007) FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 46:32–36
11. Guha IN, Parkes J, Roderick P et al (2008) Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. Hepatology 47:455–460
12. Angulo P, Hui JM, Marchesini G et al (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846–854
13. Price J, Reynolds R, Mitchell R et al (2008) The Edinburgh Type 2 Diabetes study: study protocol. BMC Endocr Disord 8:18
14. Marioni RE, Strachan MWJ, Reynolds RM et al (2010) Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh Type 2 Diabetes study. Diabetes 59:710–713
15. Morling JR, Strachan MWJ, Hayes PC et al (2012) Prevalence of abnormal plasma liver enzymes in older people with Type 2 diabetes. Diabet Med 29:488–491
16. Prineas RJ, Crow RS, Zhang Z (2010) The Minnesota code manual of electrocardiographic findings, 2nd edn. Springer, London, Available from http://link.springer.com/book/10.1007/978-1-84882-778-3, accessed 13 March 2015
17. Royal College of Physicians (2011) Science and Technology Select Committee. Inquiry on alcohol guidelines. Royal College of Physicians, London
18. Chalasani N, Younossi Z, Lavine JE et al (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:2005–2023
19. Alvarez F, Berg PA, Bianchi FB et al (1999) International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31:929–938
20. Williamson RM, Perry E, Glancy S et al (2011) The use of ultrasound to diagnose hepatic steatosis in type 2 diabetes: intra- and interobserver variability and comparison with magnetic resonance spectroscopy. Clin Radiol 66:434–439
21. Emlen W, Niebur J, Flanders G, Rutledge J (1996) Measurement of serum hyaluronic acid in patients with rheumatoid arthritis: correlation with disease activity. J Rheumatol 23:974–978
22. Williamson RM, Price JF, Glancy S et al (2011) Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 34:1139–1144
23. Monami M, Bardini G, Lamanna C et al (2008) Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism 57:387–392
24. Lee D-H, Silventoinen K, Hu G et al (2006) Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28 838 middle-aged men and women. Eur Heart J 27:2170–2176
25. Lee DS, Evans JC, Robins SJ et al (2007) Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 27:127–133
26. Lee D-H, Buijsse B, Steffen L, Holtzman J, Luepker R, Jacobs DR Jr (2009) Association between serum gamma-glutamyltransferase and cardiovascular mortality varies by age: the Minnesota Heart Survey. Eur J Cardiovasc Prev Rehabil 16:16–20
27. Emdin M, Passino C, Michelassi C, Donato L, Pompella A, Paolicchi A (2009) Additive prognostic value of gamma-glutamyltransferase in coronary artery disease. Int J Cardiol 136:80–85
28. Strasak AM, Kelleher CC, Klenk J et al (2008) Longitudinal change in serum gamma-glutamyltransferase and cardiovascular disease mortality: a prospective population-based study in 76,113 Austrian adults. Arterioscler Thromb Vasc Biol 28:1857–1865
29. Hozawa A, Okamura T, Kadowaki T et al (2007) γ-Glutamyltransferase predicts cardiovascular death among Japanese women. Atherosclerosis 194:498–504
30. Kazemi-Shirazi L, Endler G, Winkler S, Schickbauer T, Wagner O, Marsik C (2007) Gamma glutamyltransferase and long-term survival: is it just the liver? Clin Chem 53:940–946
31. Grundy SM (2007) Gamma-glutamyl transferase: another biomarker for metabolic syndrome and cardiovascular risk. Arterioscler Thromb Vasc Biol 27:4–7
32. D’Agostino RB, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care the Framingham Heart Study. Circulation 117:743–753
33. Schooling CM, Kelvin EA, Jones HE (2012) Alanine transaminase has opposite associations with death from diabetes and ischemic heart disease in NHANES III. Ann Epidemiol 22:789–798
34. Schindhelm RK, Dekker JM, Nijpels G et al (2007) Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 191:391–396
35. Stepanova M, Younossi ZM (2012) Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 10:646–650
36. Hamaguchi M, Kojima T, Takeda N et al (2007) Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 13:1579
37. Targher G, Bertolini L, Padovani R et al (2006) Increased prevalence of cardiovascular disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med 23:403–409
38. Targher G, Bertolini L, Padovani R et al (2007) Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30:1212–1218
39. Powell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell W (1990) The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11:74–80
40. Soderberg C, Stal P, Askling J et al (2010) Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 51:595–602
41. Lazo M, Hernaez R, Bonekamp S et al (2011) Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 343:d6891
42. Kim D, Kim W, Kim HJ, Therneau TM (2013) Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57:1357–1365
43. D’Amico G, Garcia-Tsao G, Pagliaro L (2006) Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44:217–231
44. Kamath PS, Wiesner RH, Malinchoc M et al (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33:464–470